Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlobalData Plc
  6. News
  7. Summary
    DATA   GB00B87ZTG26


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GlobalData : Upcoming LBPs could be the answer for GI patients with no approved treatments, says GlobalData

07/30/2021 | 12:49pm EDT
30 Jul 2021
Upcoming LBPs could be the answer for GI patients with no approved treatments, says GlobalData
Posted in Pharma

Live biotherapeutic products (LBPs), which target microbial communities in the skin and gastrointestinal (GI) and respiratory tracts, are expected to offer hope to groups of irritable bowel syndrome patients that currently have no US- or EMA-approved treatment options, according to GlobalData. The leading data and analytics company highlights the example of 4D Pharma's Blautix, which could be the first ever product to treat patients with IBS that are experiencing both constipation and diarrhea side effects (IBS-M), and notes that this is simply one of 23 exciting microbiome-targeting therapeutics currently in development in the US and 5EU* for GI, dermatological and respiratory conditions.

Chris Pilis, Pharma Analyst at GlobalData, comments: 'There is great potential for LBPs such as Blautix. IBS-M accounts for one third of IBS cases, according to GlobalData, and this drug is expected to claim an exclusive market share and provide substantial return on investment.'

According to the company's latest report, 'Thematic Research: Microbiome Targeting Therapeutics in Immunology', one great barrier of LBPs is that the field still lacks defined regulations.

Pilis continues: 'Despite the recent re-definition of these drugs, there are no current guidelines specific to new drug applications (NDA) for LBPs established in the 6MM**. However, this is expected to be addressed in the coming years as more therapies approach late-stage trials.

The majority of the LBP drugs in the pipeline target GI indications, and four are in late-stage Phase II trials, including Blautix. These drugs are expected to launch within the next five to six years. This growing class of drugs is set to challenge existing treatments such as low-priced corticosteroids in atopic dermatitis or expensive biologics in ulcerative colitis. Payors interviewed by GlobalData noted that, if priced correctly for the indication, microbiome-targeting therapies could see good market access and strong uptake by patients.

Pilis adds: 'To date, there are still no marketed microbiome-targeting products, the only available therapy being experimental fecal microbiota transplantation. Big names such as Takeda and Johnson & Johnson have recently entered the field, either alone or in partnership with other companies. However, the development of microbiome-targeting therapies is currently dominated by small- to mid-size biotech companies.

'The microbiome is a space with ample opportunity for companies, as indicated by the current lack of marketed products. There are plenty of strong candidates in the pipeline already, but, as these are largely being developed by small biotechnology companies, partnerships with larger pharmaceutical companies will eventually be required to break into the market. The field of microbiome-targeting therapies is still in its early days and the regulatory and competitive landscape is expected to be dynamic over the next decade.

'Key opinion leaders (KOLs) interviewed by GlobalData were optimistic about the tolerability and efficacy profiles of the late-stage microbiome-targeting pipeline therapies. They said that they would happily use these products as add-ons to existing therapeutic regimens or even as alternatives should they make it to market. However, KOLs remain reserved regarding long-term safety data and the maintenance of the therapeutic outcome after treatment.'

* 5EU = France, Germany, Italy, Spain and the UK

** 6MM = US and 5EU


GlobalData plc published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 16:48:11 UTC.

ę Publicnow 2021
All news about GLOBALDATA PLC
01:52pGLOBALDATA : Q-commerce is rapidly emerging as the next big delivery option, says GlobalDa..
01:52pGLOBALDATA : India continues modernization with a strong focus on indigenization, says Glo..
01:52pGLOBALDATA : UK-based start-ups raised US$19.6bn VC funding during January to August 2021
01:52pGLOBALDATA : US start-ups raked in US$219.3bn VC funding during first eight months of 2021
09:51aGLOBALDATA : US start-ups raked in US$219.3bn VC funding during first eight months of 2021..
05:42aGLOBALDATA : Halal make-up gains momentum in Indonesia, finds GlobalData
05:42aGLOBALDATA : Japan to be one of the world's smartest societies by 2030, says GlobalData
05:42aGLOBALDATA : From Flipkart to Zomato Indian startups raise US$20.5bn VC funding during Jan..
05:42aGLOBALDATA : Delays in availability will impact overall market potential of recently appro..
09/23GLOBALDATA : Loss of touch, inconsistent video call technology are key drivers for doctors..
More news
Sales 2021 192 M 262 M 262 M
Net income 2021 27,9 M 38,1 M 38,1 M
Net Debt 2021 50,8 M 69,4 M 69,4 M
P/E ratio 2021 65,8x
Yield 2021 1,23%
Capitalization 1 740 M 2 379 M 2 379 M
EV / Sales 2021 9,35x
EV / Sales 2022 8,61x
Nbr of Employees 3 472
Free-Float 30,8%
Duration : Period :
GlobalData Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 1 475,00 GBX
Average target price 1 592,50 GBX
Spread / Average Target 7,97%
EPS Revisions
Managers and Directors
Michael Thomas Danson Chief Executive Officer & Director
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Murray Legg Independent Non-Executive Chairman
Peter Martin Harkness Independent Non-Executive Director
Catherine Birkett Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
S&P GLOBAL INC.37.83%108 799
RELX PLC23.57%58 657
MSCI INC.48.11%53 883
EQUIFAX INC.37.48%32 301